
Arpeggio Bio
Arpeggio Bio is a YC Summer 2019 (S19) company. Based in Boulder, CO, USA. Team of 20.
About Arpeggio Bio
Summary
Arpeggio Bio develops small-molecule drugs against transcription factors, a class of proteins historically considered undruggable, using AI and high-throughput RNA sequencing. Its platform identifies compounds that modulate targets such as NRF2, TEAD, and GPX4, replacing the manual, low-throughput screening methods that have long stalled drug discovery in this space. The lead program targets IO-resistant melanoma, and the platform has been applied to rare disease and inflammation through pharmaceutical partnerships.
From the Y Combinator listing
Arpeggio Bio develops drugs targeting transcription factors using AI…
Arpeggio Bio is a pioneering pharmaceutical company that develops drugs targeting transcription factors using AI and high-throughput RNA-sequencing. With $20M in venture funding, we've targeted "undruggable" proteins like NRF2, TEAD, and GPX4 where our lead program is rapidly progressing towards a DC for the treatment of IO-resistant melanoma. With partnerships with J&J and FORMA, we've validated our platform in rare disease and inflammation with a significant Phase I success.
Facts
- Healthcare / Healthcare -> Drug Discovery and Delivery
- Boulder, CO, USA
- 20
- Active
- Early
Founders (1)
- Joey Azofeifa
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works